 Shares of Qiagen N.V. slumped 4.5 in morning trading Monday, reversing an earlier intraday gain of as much 1.7, after the Netherlands-based biotechnology company provided an upbeat second-quarter revenue outlook, citing stronger-than-expected sales of non-COVID product groups, but also a downbeat third-quarter estimate. 